Bellevue Group AG raised its stake in Myovant Sciences Ltd. (NYSE:MYOV) by 1.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,269,039 shares of the company’s stock after purchasing an additional 75,000 shares during the quarter. Myovant Sciences comprises approximately 1.2% of Bellevue Group AG’s holdings, making the stock its 23rd biggest holding. Bellevue Group AG owned approximately 5.72% of Myovant Sciences worth $119,976,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in MYOV. Quantbot Technologies LP acquired a new position in shares of Myovant Sciences during the 1st quarter valued at $28,000. Royal Bank of Canada increased its stake in Myovant Sciences by 211.6% during the 1st quarter. Royal Bank of Canada now owns 1,480 shares of the company’s stock worth $31,000 after buying an additional 1,005 shares during the period. Citigroup Inc. increased its stake in Myovant Sciences by 56.8% during the 1st quarter. Citigroup Inc. now owns 1,620 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the period. BNP Paribas Arbitrage SA increased its stake in Myovant Sciences by 4,336.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,771 shares of the company’s stock worth $78,000 after buying an additional 3,686 shares during the period. Finally, Pinz Capital Management LP purchased a new stake in Myovant Sciences during the 1st quarter worth $121,000. Institutional investors own 33.78% of the company’s stock.
Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Myovant Sciences in a research note on Friday, August 20th. They set a “neutral” rating and a $18.00 price target on the stock. SVB Leerink assumed coverage on shares of Myovant Sciences in a research report on Thursday, September 9th. They issued a “market perform” rating and a $24.00 target price for the company. Zacks Investment Research downgraded shares of Myovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, August 10th. Finally, JMP Securities reissued a “buy” rating on shares of Myovant Sciences in a research report on Wednesday, August 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $25.57.
NYSE MYOV opened at $23.57 on Monday. Myovant Sciences Ltd. has a one year low of $13.42 and a one year high of $30.90. The company has a 50-day simple moving average of $22.20 and a 200-day simple moving average of $21.67. The firm has a market capitalization of $2.17 billion, a PE ratio of -7.53 and a beta of 2.87.
Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings results on Wednesday, July 28th. The company reported ($0.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.46). The firm had revenue of $41.06 million for the quarter, compared to analyst estimates of $61.19 million. Equities research analysts expect that Myovant Sciences Ltd. will post -2.24 earnings per share for the current year.
Myovant Sciences Profile
Myovant Sciences, Inc is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women’s health and endocrine diseases. It offers ORGOVYXTM (relugolix), a oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer.
Featured Story: What is the operating income formula?
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.